Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?

Gut microbiota plays a role in the pathophysiology of metabolic diseases, which include nonalcoholic fatty liver diseases, through the gut-liver axis. To date, clinical guidelines recommend a weight loss goal of 7%-10% to improve features of nonalcoholic fatty liver diseases. Because this target is not easily achieved by all patients, alternative therapeutic options are currently being evaluated. This review focuses on therapeutics that aim to modulate the gut microbiota and the gut-liver axis. We discuss how probiotics, prebiotics, synbiotic, fecal microbiota transfer, polyphenols, specific diets, and exercise interventions have been found to modify gut microbiota signatures; improve nonalcoholic fatty liver disease outcomes; and detail, when available, the different mechanisms by which these beneficial outcomes might occur. Apart from probiotics that have already been tested in human randomized controlled trials, most of these potential therapeutics have been studied in animals. Their efficacy still warrants confirmation in humans using appropriate design.

Aron-Wisnewsky J ，Warmbrunn MV ，Nieuwdorp M ，Clément K ... -  《-》

Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease.

Suk KT ，Kim DJ 《-》

The intestinal microbiota as a therapeutic target in the treatment of NAFLD and ALD.

Liver diseases are currently common disorders worldwide. Especially, the proportion of patients with nonalcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) is growing globally. An increasing number of studies have revealed a close relationship between the intestinal microbiota and the development of NAFLD and ALD. A better understanding of the role of intestinal microbiota and the intestine-liver axis thus might lead to the development novel therapies for the treatment of these diseases.

Huang W ，Kong D 《-》

Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics.

Cho MS ，Kim SY ，Suk KT ，Kim BY ... -  《-》

Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.

Han R ，Ma J ，Li H 《-》